Modulating neuromuscular junction density changes in botulinum-toxin treated tissue
US8791072B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 27, 2012 |
| Grant date | Jul 29, 2014 |
| Priority date | — |
| Expiry date | Feb 27, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method may include administering botulinum toxin to a tissue of a patient and administering a neuropeptide of the CRF family to the tissue of the patient. In some examples, the botulinum toxin is periodically administered to the tissue of the patient and/or the neuropeptide of the CRF family is periodically administered to the tissue of the patient. The periods with which the botulinum toxin and the neuropeptide of the CRF family are administered may be the same or may be different. In some examples, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at substantially the same time, while in other embodiments, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at different times.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.